Research Associate I/II

Experience working in a regulated laboratory environment (CLIA, GLP/GCLP, IVD development).

Experience with automated platforms in plate-based, low-volume formats and/or microfluidics and experience working with automated liquid handlers.

Experience using ELN (electronic lab notebook) and LIMS (lab information management system).

Familiarity with programing in a scientific programming language (e.g., Python or R).

The US target range of our

base hourly rate

for new hires is $37.68 - $46.69

. You will also be eligible to receive equity, cash bonuses, and a full range of medical, financial, and other benefits depending on the position offered.  Please note that individual total compensation for this position will be determined at the Company’s sole discretion and may vary based on several factors, including but not limited to, location, skill level, years and depth of relevant experience, and education. We invite you to check out our career page @

freenome.com/job-openings/

for additional company information.

At Freenome, you will help develop the assay technologies used to analyze patient samples and contribute to our mission of early detection and intervention in human disease.

As a Research Associate I/II, you will provide experience in next-generation-sequencing (NGS)-based analyses of DNA.

Starting with a prototype assay, you will contribute to developing and validating clinical-grade assays to measure complex, blood-based analytes.

You will work closely with multiple teams including molecular research, computational science, automation engineering, and clinical operations to develop the assays in a regulated, high-throughput environment as well as identify ways to rapidly iterate and improve on existing methods to evaluate technologies that can enhance our end-to-end test performance.

The role reports to the Senior Manager and Staff Research Scientist.

Apply knowledge of molecular biology, nucleic-acid biochemistry, and next-generation sequencing to develop assays for DNA.